|本期目录/Table of Contents|

[1]杨伟光,喇焕之,张元桢.营养状态及血液常规指标对肺腺癌免疫不良反应的预测分析[J].中华肺部疾病杂志,2023,(06):829-832.[doi:10.3877/cma.j.issn.1674-6902.2023.06.018]
点击复制

营养状态及血液常规指标对肺腺癌免疫不良反应的预测分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年06期
页码:
829-832
栏目:
临床研究
出版日期:
2023-12-20

文章信息/Info

Title:
-
作者:
杨伟光1; 喇焕之1; 张元桢2
200433 上海,同济大学附属上海市肺科医院胸外科1
210029 南京,南京医科大学第一附属医院骨科2
Author(s):
-
关键词:
肺腺癌;  营养;  免疫相关不良反应;  预测意义
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2023.06.018
摘要:
目的 分析营养状态及血液常规指标对肺腺癌免疫不良反应的预测意义。方法 选择2021年6月至2023年4月我院收治的69例经PD-1治疗的Ⅲ期和Ⅳ期肺腺癌患者为对象,发生免疫相关不良反应39例分为观察组,未发生免疫相关不良反应30例分为对照组。利用NRS2002评分系统评估两组营养状态,NLR、PLR及其他实验检查指标。单因素和多因素Logistic回归分析肺腺癌免疫不良反应的危险因素,ROC曲线评估预测。结果 单因素分析显示营养状态、年龄、中性粒细胞计数、淋巴细胞计数、C-反应蛋白、血小板计数、中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio, NLR)、血小板与淋巴细胞比值(platelet to lymphocyte ratio, PLR)是影响肺腺癌发生免疫不良反应的相关因素(P<0.05)。观察组营养不良27例(69.2%),对照组12例(40.0%)(P=0.015)。观察组≥65岁29例(74.4%),对照组8例(26.6%)(P<0.05)。观察组与对照组NLR和PLR分别(7.44±2.41 vs. 3.45±1.08);(296.94±59.01 vs. 190.47±40.32)(P<0.05)。ROC曲线分析显示营养状态、年龄、PLR曲线下面积分别为0.694、0.7932、0.7188,营养状态、年龄≥65岁和高PLR为发生免疫相关不良反应的危险因素(P<0.05)。结论 营养状态、年龄、PLR可作为肺腺癌发生免疫不良反应的预测因素,具有临床意义。
Abstract:
-

参考文献/References:

1 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
2 Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
3 Dlamini SB, Sartorius B, Ginindza TG. Pre- and post-intervention survey on lung cancer awareness among adults in selected communities in KwaZulu-Natal, South Africa: A quasi-experimental study[J]. J Public Health Africa, 2023, 14(1): 2131.
4 Alexander M, Kim SY, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer[J]. Lung, 2020, 198(6): 897-907.
5 Miyazawa T, Marushima H, Saji H, et al. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes[J]. Ann Thorac Cardiovasc Surg, 2019, 25(1): 1-9.
6 Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics[J]. J Hematol Oncol, 2019, 12(1): 92.
7 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nature Reviews Cancer, 2012, 12(4): 252-264.
8 Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression[J]. Ann Oncol, 2019, 30(10): 1653-1659.
9 Lee DJ, Lee HJ, Jr., Farmer JR, et al. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors[J]. Current Cardiol Reports, 2021, 23(8): 98.
10 Kitagawa S, Hakozaki T, Kitadai R, et al. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review[J]. Thorac Cancer, 2020, 11(7): 1927-1933.
11 Polański J, Chabowski M, Switoniowska-Lonc N, et al. Relationship between nutritional status and clinical outcome in patients treated for lung cancer[J]. Nutrients, 2021, 13(10): 3332.
12 曾 燕, 东 燕, 刘军妮. NRS-2002评分与PG-SGA评分法在老年消化道肿瘤患者中的应用[J]. 齐鲁护理杂志, 2021, 27(19): 76-79.
13 王会杰, 孙珍贵, 赵文英, 等. S100A10可促进肺腺癌细胞的增殖和侵袭:基于激活Akt-mTOR信号通路[J]. 南方医科大学学报, 2023, 43(5): 733-740.
14 Tan D, Wang S, Zhang P, et al. LncRNA SNHG12 decreases non-small cell lung cancer cell sensitivity to cisplatin by repressing miR-525-5p and promoting XIAP[J]. Ann Clin laborat Sci, 2023, 53(1): 64-75.
15 Song M, Zhang Q, Song C, et al. The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer[J]. J Cachexia Sarcopenia Muscle, 2022, 13(5): 2504-2514.
16 张 正. 影响胃癌术后化疗患者营养状态的危险因素分析[J]. 吉林医学, 2022, 43(7): 2008-2010.
17 Grisold W, Löscher W, Grisold A. Neurological complications of systemic tumor therapy[J]. Wien Med Wochenschr, 2019, 169(1-2): 33-40.
18 Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review[J]. J Am Acad Dermatol, 2009, 61(3): 486-504.
19 Serra López-Matencio JM, Gómez Garcia De Soria V, Gómez M, et al. Monitoring and safety of CAR-T therapy in clinical practice[J]. Expert Opin Drug Saf, 2022, 21(3): 363-371.
20 Bustillos H, Indorf A, Alwan L, et al. Xerostomia: an immunotherapy-related adverse effect in cancer patients[J]. Support Care Cancer, 2022, 30(2): 1681-1687.
21 Peterson SJ, Mozer M. Differentiating sarcopenia and cachexia among patients with cancer[J]. Nutr Clin Pract, 2017, 32(1): 30-39.
22 Polański J, Jankowska-Polańska B, Uchmanowicz I, et al. Malnutrition and quality of life in patients with non-small-cell lung cancer [J]. Adv Exp Med Biol, 2017, 1021: 15-26.
23 Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study[J]. Scientific Reports, 2019, 9(1): 2447.
24 Bacha S, Mejdoub El Fehri S, Habibech S, et al. Impact of malnutrition in advanced non-small cell lung cancer[J]. Tunis Med, 2018, 96(1): 59-63.
25 岳 岚, 李 珍, 李锡清, 等. 衰弱及血常规指标对肿瘤病人发生免疫相关不良反应的预测价值研究[J]. 全科护理, 2022, 20(9): 1153-1156.
26 Niemeläinen S, Huhtala H, Andersen J, et al. The Clinical Frailty Scale is a useful tool for predicting postoperative complications following elective colon cancer surgery at the age of 80 years and above: A prospective, multicentre observational study[J]. Colorectal Dis, 2021, 23(7): 1824-1836.
27 Guo J, Yang Q, Jiang Q, et al. Integrating baseline nutritional and inflammatory parameters with post-treatment EBV DNA level to predict outcomes of patients with De Novo metastatic nasopharyngeal carcinoma receiving chemotherapy combination PD-1 inhibitor[J]. Nutrients, 2023, 15(19): 4262.
28 Vetrano DL, Triolo F, Maggi S, et al. Fostering healthy aging: The interdependency of infections, immunity and frailty[J]. Ageing Res Rev, 2021, 69: 101351.
29 Egami S, Kawazoe H, Hashimoto H, et al. Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study[J]. J Cancer, 2021, 12(7): 2105-2112.
30 Trestini I, Sperduti I, Sposito M, et al. Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome[J]. ESMO open, 2020, 5(3): e000689.
31 Kichenadasse G, Miners JO, Mangoni AA, et al. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer[J]. JAMA Oncol, 2020, 6(4): 512-518.
32 Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio(NLR)and Platelet-to-Lymphocyte ratio(PLR)as prognostic markers in patients with non-small cell lung cancer(NSCLC)treated with nivolumab[J]. Lung Cancer, 2017, 111: 176-181.

备注/Memo

备注/Memo:
基金项目: 上海市 2022 年度“科技创新行动计划”医学创新研究专项项目(22Y11901800)
通信作者: 杨伟光, Email: m18221095087_1@163.com
更新日期/Last Update: 2023-12-20